TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07419334: Study of ALK-001 on the Progression of Stargardt Disease

Sponsor: Alkeus Pharmaceuticals, Inc. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 230 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$2,592,920

Rescue Site Savings

+$1,697,184

Unlock Full NCT07419334 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07419334 Rescue Dossier →